|
|
|
51-200 employees
View all
|
|
biotechnology
|
|
10628 Science Center Drive,San Diego,CA,US
|
|
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
|
Turning Point Therapeutics Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
75%
|
The widely used Turning Point Therapeutics email format is {first}.{last} (e.g. [email protected]) with 75% adoption across the company.
To contact Turning Point Therapeutics customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.